a close relative of the investigator, dependent person (e.g. Close affiliation with the investigational site e.g.Inability to adhere to study procedures.Female of childbearing potential who are not surgically sterile, or, if sexually active not willing to use adequate contraceptive measures with a failure rate less than 1% per year (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, male partner sterilization) before entry and throughout the study, as well as pregnant or breast-feeding women.Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4) and P-glycoprotein (P-gp), i.e., human immunodeficiency virus protease inhibitors and the following azole-antimycotics agents: ketoconazole, itraconazole, voriconazole, or posaconazole, if used systemically.Known hypersensitivity to either ASA or rivaroxaban.Uncontrollable hypertension with systolic BP/ diastolic BP consistently above180/100mmHg after treatment.Platelet count less than 100,000/mm3 at enrolment or other bleeding diathesis BACKGROUND Intracranial atherosclerotic disease (ICAD) is one of the most common causes of stroke worldwide and is associated with a high risk of stroke.Advanced kidney disease (recent estimated GFR =4 at entry.Traumatic brain hemorrhage within 1 month of randomization.intracerebral or subarachnoid hemorrhage) Previous spontaneous hemorrhagic stroke (e.g.Subdural hematoma within 12 months of randomization.Extracranial carotid artery disease ipsilateral to the qualifying brain ischemia with a plan for carotid revascularization.Intracranial arterial stenosis secondary to causes other than atherosclerosis.100% stenosis) responsible for the acute brain ischemia While we are proposing future studies to reduce recurrent ICAD stroke risk, it should be noted that, in the long term, our research may lead to effective primary ICAD stroke risk reduction through PCSK9 inhibition in patients at high risk of stroke identified through asymptomatic stenosis, post-contrast plaque enhancement (PPE) or intraplaque hemorrhage (IPH) on vwMRI. Atrial fibrillation or a history of atrial fibrillation.patient with prosthetic mechanical valve, venous thromboembolism, hypercoagulable state Indication for chronic anticoagulation based on guideline recommendations or investigator ́s judgment e.g.Indication for DAPT for > 90 days on guideline recommendations or investigator ́s judgment e.g., cardiac stenting.Written informed consent consistent with local regulations governing research in human subjects.
#Icad stroke plus
a high-risk TIA defined as TIA with motor and/or speech involvement or CATIS-ICAD is the first pilot RCT assessing safety of low-dose rivaroxaban plus ASA in patients with recent ischemic stroke/high-risk TIA secondary to.Recent brain ischemia attributed to intracranial atherosclerotic stenosis of 30-99% as evidenced by CT or MR angiography, occurring between 7 to 100 days prior to randomization and consisting of either: There are several possible mechanisms of ischemic stroke in the ICAD patients: artery to artery embolism, hypoperfusion and branch atheromatous disease and. Why Should I Register and Submit Results?.